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Conclusions This post-hoc analysis from the ELISA-3 trial 
suggests that NSTE-ACS patients initially hospitalised in 
non-PCI centres show the largest benefit from early angiog-
raphy and revascularisation, associated with a shorter wait-
ing time to revascularisation. Improved patient logistics and 
transfer between non-PCI and PCI centres might therefore 
result in better clinical outcome.
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Introduction
A routinely invasive strategy (angiography and revasculari-
sation if applicable) is recommended by the current guide-
lines [1, 2] in high-risk patients with non-ST-elevation acute 
coronary syndrome (NSTE-ACS). The majority of trials 
and meta-analysis on this topic showed a reduction in the 
incidence of cardiovascular death and myocardial infarc-
tion (MI) in the medium to long term [3–9], although for 
example the Dutch Ictus study (Invasive versus Conserva-
tive Treatment in Unstable Coronary Syndromes [10]) did 
not. Studies investigating optimal timing of intervention 
showed conflicting results. Meta-analysis of randomised 
controlled trials (RCTs) [11, 12] and observational studies 
[13] comparing early to later timing showed that early tim-
ing of intervention does not lead to a reduction in the inci-
dence of death or myocardial infarction but at most reduces 
the incidence of recurrent ischaemia.
A limitation of these studies is that they were largely con-
ducted in tertiary care, high-volume, percutaneous coronary 
intervention (PCI) centres. In the Netherlands, as in many 
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Abstract
Aims To compare the effect of timing of intervention in 
patients with non-ST-elevation acute coronary syndrome 
(NSTE-ACS) in percutaneous coronary intervention (PCI) 
versus non-PCI centres.
Methods and results A post-hoc sub-analysis was per-
formed of the ELISA III trial, a randomised multicentre trial 
investigating outcome of early (< 12 h) versus late (> 48 h) 
angiography and revascularisation in 542 patients with high-
risk NSTE-ACS. 90 patients were randomised in non-PCI 
centres and tended to benefit more from an early invasive 
strategy than patients included in the PCI centre (relative 
risk 0.23 vs. 0.85 [p for interaction = 0.089] for incidence 
of the combined primary endpoint of death, reinfarction and 
recurrent ischaemia after 30 days of follow-up). This was 
largely driven by reduction in recurrent ischaemia. In non-
PCI centres, patients randomised to the late group had a 4 
and 7 day longer period until PCI or coronary artery bypass 
grafting, respectively. This difference was less pronounced 
in the PCI centre.
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Patients
After giving written informed consent, patients were ran-
domly assigned to an immediate or delayed treatment 
strategy. In patients assigned to the immediate treatment 
strategy, angiography was performed as soon as possible 
but within 12 h of randomisation. Patients assigned to 
the delayed treatment strategy underwent angiography no 
sooner than 48 h after randomisation unless, despite optimal 
medical therapy, clinical instability or recurrent ischaemia 
warranted emergency angiography. Patients recruited at a 
non-PCI centre and randomised to the immediate interven-
tion group were urgently transferred to the PCI centre for 
angiography and subsequent revascularisation; in case of 
assignment to delayed intervention, angiography was per-
formed at the non-PCI centre and the patient was transferred 
to the PCI centre for intervention if necessary. All patients 
were treated according to the current guidelines.
Endpoints
Primary endpoint of the ELISA-3 study as well for the cur-
rent sub-analysis was the combined incidence of all-cause 
mortality, re-infarction and/or recurrent ischaemia at 30-day 
follow-up. Secondary endpoints were enzymatic infarct size 
as assessed by a single cardiac troponin T, at 72–96 h after 
admission or at discharge and the percentage of patients 
without a rise in CK-MB during admission. In addition, 
bleeding complications were assessed. Major bleeding was 
defined as bleeding with a haemoglobin drop of ≥ 2 mmol/l 
or a blood transfusion of 2 or more units. All endpoints were 
adjudicated by an independent endpoint committee.
Statistical analysis
Data were analysed according to the intention-to-treat anal-
ysis. Continuous variables were expressed as median and 
interquartile range (IQR) and were compared between the 
intervention groups using a Mann-Whitney U test. Categori-
cal data were described by proportions and compared with the 
Chi square or Fisher’s exact test. Logistic regression was used 
to calculate the p-value of the interaction between the effect of 
the intervention and the subgroups upon the primary endpoint. 
All tests were two-sided and an alpha of 5 % was used. Statis-
tical analysis was performed with SPSS (version 20).
Results
Comparison of PCI vs. non-PCI centres
Of the total number of 542 patients in the trial, 444 (82 %) 
were included in the PCI centre and 90 in one of the 5 non-
other European countries, however, a considerable number 
of these patients are initially hospitalised in non-PCI cen-
tres. After medical stabilisation and coronary angiography, 
the patient is then transferred to the PCI centre for revas-
cularisation, if needed. This makes generalisability of the 
study results to clinical practice questionable.
Observational studies [14, 15] showed that patients admit-
ted to a centre with angiography and PCI facilities were 
more likely to receive an invasive strategy, had a lower risk 
for refractory or recurrent angina at the cost of higher risk 
for stroke and major bleeding. No difference was found in 
the incidence of cardiovascular death, myocardial infarction 
or stroke at 6 months. According to the investigators, these 
findings support the strategy of directing patients with sus-
pected ACS to the nearest hospital with acute care, irrespec-
tive of the availability of interventional facilities. Because 
these studies were non-randomised and performed about 15 
years ago, when background medication was different from 
today, these data should be interpreted with caution.
The ELISA 3 trial compared an early versus delayed 
invasive strategy in a population of high-risk patients hos-
pitalised for NSTE-ACS in 6 centres (5 non-PCI and 1 PCI) 
in the Netherlands. The aim of the current sub-study is to 
investigate the clinical effect of timing of invasive strategy 
in patients randomised in the participating non-PCI centres 
and to compare this to patients randomised in the PCI centre.
Methods
The ELISA-3 study was an investigator-initiated, ran-
domised, open, multicentre study. Rationale, design and 
results have been published previously [16]. Patients were 
eligible if they were hospitalised with ischaemic chest pain 
or dyspnoea at rest and had at least 2 out of 3 of the follow-
ing high-risk characteristics: (1) evidence of extensive myo-
cardial ischaemia on ECG (shown by new cumulative ST 
depression > 5 mm or temporary ST-segment elevation in 2 
contiguous leads < 30 min), (2) elevated biomarkers (tropo-
nin T > 0.10 μg/l or myoglobin > 150 μg/l) or elevated cre-
atine kinase-myocardial band (CK-MB) fraction (> 6 % of 
total CK) and (3) age above 65 years. Randomisation had to 
take place within 24 h of the last episode of ischaemic symp-
toms. Exclusion criteria were persistent ST-segment eleva-
tion, symptoms of ongoing myocardial ischaemia despite 
optimal medical therapy, contraindication for diagnostic 
angiography, active bleeding, cardiogenic shock, acute pos-
terior infarction and life expectancy less than 1 year. The 
trial was conducted in six Dutch hospitals of which one had 
24-hour facilities for (primary) PCI and coronary artery 
bypass grafting (CABG). The study was registered in the 
ISRCTN Register (ISRCTN39230163).
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Discussion
This sub-study, comparing the effect of timing of inter-
vention in high-risk non-ST-elevation acute coronary syn-
dromes between patients hospitalised in PCI and non-PCI 
centres shows that non-PCI centre patients tend to benefit 
more from an early invasive strategy, mainly due to reduc-
tion in recurrent ischaemia. These results were found in 
relationship to a much larger difference in revascularisation 
times between early and late treated patients in the patients 
admitted primarily in a non-PCI centre.
In patients initially hospitalised in non-PCI centres, 
median time from coronary angiography to revascularisa-
tion was longer in those randomised to a delayed strategy 
compared with an early invasive strategy (Fig. 2). This was 
caused by a difference in patient logistics: patients ran-
domised to an immediate strategy were urgently transferred 
to the PCI centre where the coronary angiography and—
when appropriate—in the same procedure a PCI was per-
formed. Patients randomised to a delayed invasive strategy 
underwent a coronary angiography in the non-PCI centre 
and underwent a PCI later on, after their angiogram had been 
discussed with the heart team consisting of interventional 
cardiologists and thoracic surgeons, and transfer to the PCI 
centre. This resulted in an additional waiting time after angi-
ography of 4 days for PCI and even 7 days for CABG. For 
patients randomised in the PCI centre, this difference did 
not occur, because all patients underwent coronary angiog-
raphy and PCI (if feasible) in the same procedure, irrespec-
tive of the group they were randomised to. Median waiting 
time for CABG in patients hospitalised in the PCI centre 
was 123 h (5.1 days), comparable with patients randomised 
to the early invasive strategy in non-PCI centres.
This difference in logistics of patients with NSTE-ACS 
between PCI and non-PCI centres also exists in daily prac-
tice. In PCI centres, angiography and revascularisation are 
generally performed in the same procedure, while patients 
in non-PCI centres first undergo a coronary angiography, 
then are discussed with the team of the PCI centre and are 
scheduled for revascularisation a couple of days later. In the 
meantime, these patients are prone to developing recurrent 
ischaemic symptoms, as can been seen in the Kaplan-Meyer 
curve of this group of patients for event-free survival from 
recurrent ischaemia in the first week (Fig. 3). Considering 
this, shortening the time between angiography and revas-
cularisation might reduce the recurrence of ischaemia and 
improve clinical outcome in patients initially hospital-
ised in a non-PCI centre. Agreements with PCI centres to 
assure short access time for revascularisation and applica-
tion of information technologies for fast distant evaluation 
of angiograms may be helpful. Periodic national audits, as 
for example snapshot registries of the National Cardiovas-
cular Data Registry (NCDR), could be used to monitor the 
PCI centres. Eight patients were excluded, 5 for withdrawn 
consent and 3 for major protocol violations. Baseline charac-
teristics and clinical outcome are shown in Table 1. Patients 
in non-PCI centres were older and there were less smokers. 
Time from admission to randomisation was comparable. 
Time from randomisation to start of angiography was longer 
in the non-PCI centres (23.8 vs. 15.1 h, p = 0.07) as was time 
from angiography to PCI (0.75 vs. 0.37 h, p < 0.001) and 
angiography to CABG (122.8 vs. 189.9 h, p = 0.037). No 
difference was found in the incidence of the primary end-
point between the two groups or in the individual compo-
nents. The percentage of patients without a rise in CK-MB 
during admission was significantly higher in patients from 
the non-PCI centres (52.6 vs. 33.1 %, p = 0.01). Incidence of 
bleeding events was comparable.
Effect of early vs. delayed treatment in patients 
included in non-PCI centres
Of the 90 patients who were included in a non-PCI centre, 
45 (50 %) were randomised to immediate treatment and 45 
to a delayed invasive treatment strategy. Baseline charac-
teristics were largely comparable (Table 2), with exception 
of gender and percentage of smokers. As intended by the 
protocol, median time from randomisation to angiography 
was 3.0 h in the immediate and 70 h in the delayed treatment 
group. In addition, time from the start of the coronary angi-
ography to revascularisation (PCI or CABG, if any) was 0.7 
vs. 146 h; for PCI 0.37 vs. 96.5 h [4.0 days] and for CABG 
115 [4.8 days] vs. 275 h [11.5 days]. The combined primary 
endpoint occurred in 4.7 % of the patients in the immediate 
treatment group and 20.5 % of the patients in the delayed 
treatment group (p = 0.027). This difference was driven by 
a reduction in the occurrence of recurrent ischaemia in the 
immediately treated patients (2.3 vs. 18.2 %, p = 0.03 in the 
immediate and delayed treatment group respectively).The 
incidence of the secondary endpoints and bleeding events 
did not differ.
Effect of timing of intervention in patients from PCI 
centre vs. non-PCI centres
The effect of the timing of the intervention on the primary 
endpoint is shown in Fig. 1. Patients included in a non-PCI 
centre tended to benefit more from an early invasive strat-
egy than those included in the PCI centre (relative risk 0.23 
vs. 0.85) but this difference was not statistically signifi-
cant (p-value for interaction = 0.089) and largely driven by 
reduction in recurrent ischaemia. No differences were found 
in the incidence of secondary endpoints and bleeding.
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compare outcome in these two types of centres. No signifi-
cant differences in clinical outcome were found, showing 
that initial medical stabilisation and angiography in non-
PCI centres is safe and feasible.
This study has the following limitations. Clinical charac-
teristics of both patient groups differ. For example, slightly 
more patients in the PCI centre had no significant coronary 
artery disease (11.5 vs. 8.1 %) which might have influenced 
achievement of pre-determined quality indicators. Because 
the role of the ECG in initial ACS triage is limited [17], 
other factors should also be taken into account with the 
assessment of urgency for revascularisation.
As far as we know, the ELISA 3 trial is the first ran-
domised trial investigating the effect of timing of interven-
tion in high-risk NSTE-ACS patients that included patients 
in both PCI and non-PCI centres, giving the opportunity to 
Table 1 Baseline characteristics, study endpoints and clinical outcomes of patients randomised in PCI versus non-PCI centres
PCI centre (n = 444) Non-PCI centres (n = 90) P-value
Demographics Age (years, IQR) 71.19 (62.9–78.26) 73.51 (67.84–78.41) 0.017
Male gender, n (%) 302/444 (68.0 %) 59/90 (65.6 %) 0.649
GRACE score (median, IQR) 136 (117–154) 135 (119–151) 0.877
Medical history (n,%) Hypertension 248/444 (55.9 %) 52/90 (57.8 %) 0.738
Smoking 113/444 (25.5 %) 14/90 (15.6 %) 0.044
Diabetes 102/444 (23.0 %) 16/90 (17.8 %) 0.279
Previous MI 84/444 (18.9 %) 16/90 (17.8 %) 0.800
Previous TIA 22/444 (5.0 %) 6/90 (6.7 %) 0.447
Previous stroke 20/444 (4.5 %) 1/90 (1.1 %) 0.228
Previous PCI 89/444 (20.0 %) 15/90 (16.7 %) 0.461
Previous CABG 59/444 (13.3 %) 10/90 (11.1 %) 0.574
Time (hours, median, IQR) Admission—randomisation 2.05 (1.11–4.11) 2.16 (0.08–6.36) 0.910
Randomisation angiography 15.13 (2.29–54.07) 23.83 (2.83–70.05) 0.070
Angiography—PCI 0.37 (0.18–0.65) 0.75 (0.30-93.25) < 0.001
Angiography—CABG 122.78 (49.93–230.85) 189.92 (96.78–325.27) 0.037
Angiography—revascularisation 0.47 (0.23–43.66) 69.17 (0.43-190.45) < 0.001
Extent CAD One vessel 113/434 (26.0 %) 27/86 (31.4 %) 0.494
Two vessel 144/434 (23.2 %) 24/86 (27.9 %)
Three vessel 127/434 (29.3 %) 28/86 (32.6 %)
Infarct-related artery LAD 133/382 (34.8 %) 34/79 (43.0 %) 0.340
RCA 81/382 (21.2 %) 15/79 (19.0 %)
Circumflex 90/382 (23.6 %) 22/79 (23.6 %)
Left main 7/382 (1.8 %) 1/79 (1.3 %)
Graft 34/382 (8.9 %) 4/79 (5.1 %)
Treatment PCI 254/384 (66.1 %) 44/79 (55.7 %) 0.140
CABG 87/384 (22.7 %) 26/79 (32.9 %)
Medical 43/384 (11.2 %) 9/79 (11.4 %)
Primary endpoint (%) Combined endpointa 52/436 (11.9 %) 11/87 (12.6 %) 0.851
Death 5/436 (1.1 %) 1/87 (1.1 %) > 0.99
MI 5/436 (1.1 %) 2/87 (2.3 %) 0.329
Recurrent ischaemia 44/436 (10.1 %) 9/87 (10.3 %) 0.943
Secondary endpoints Enzymatic infarct sizeb 0.31 (0.11–0.86) 0.30 (0.11–0.73) 0.918
% patients without CKMB rise 147/444 (33.1 %) 40/76 (52.6 %) 0.001
Bleeding Any bleeding 93/436 (21.3 %) 19/87 (21.8 %) 0.916
Major bleeding 52/436 (11.9 %) 8/87 (9.2 %) 0.465
CABG-related bleeding 79/436 (18.1 %) 14/87 (16.1 %) 0.652
CABG-related major bleeding 47/436 (10.8 %) 7/87 (8.0 %) 0.444
CABG coronary artery bypass graft, CAD coronary artery disease, CKMB creatine kinase-MB, IQR inter quartile range, LAD left anterior 
descending, MI myocardial infarction, PCI percutaneous coronary intervention, RCA right coronary artery, TIA transient ischaemic attack.
aCombined primary endpoint = incidence of death, reinfarction and recurrent ischaemia at 30-day follow-up.
bSingle troponin T 72–96 h after admission (µg/l, median, IQR).
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by a longer time interval between angiography and revascu-
larisation needs further investigation. If new studies were to 
confirm our hypothesis, a change in the management of this 
large group of patients might be considered.
The main finding of the ELISA-3 study was that in high-
risk NSTE-ACS patients, early angiography and revascular-
isation led to a non-significant 30 % relative risk reduction 
our findings. Further, this sub-study is based on a post-
hoc sub-group analysis with a relatively small number of 
patients. Therefore, our findings should be interpreted with 
caution. From our data, the cause of the trend towards a 
higher risk of recurrent ischaemia in patients randomised 
to delayed invasive strategy in non-PCI clinics cannot be 
proven. Therefore, our hypothesis that this might be caused 
Table 2 Baseline characteristics, study endpoints and clinical outcome of patients randomised in non-PCI centres
Early treatment (n = 45) Late treatment (n = 45) P-value
Demographics Age (years, IQR) 73.78 (69.97–78.41) 72.97 (67.55–77.97) 0.377
Male gender, n (%) 35/45 (77.8 %) 24/45 (53.3 %) 0.015
GRACE score (median, IQR) 136 (129–157) 130 (113–149) 0.406
Medical history (n,%) Hypertension 24/45 (53.3 %) 28/45 (62.2 %) 0.393
Smoking 3/45 (6.7 %) 11/45 (24.4 %) 0.020
Diabetes 6/45 (13.3 %) 10/45 (22.2 %) 0.270
Previous MI 5/45 (11.1 %) 11/45 (24.4 %) 0.098
Previous TIA 3/45 (6.7 %) 3/45 (6.7 %) > 0.99
Previous stroke 0/45 (0.0 %) 1/45 (2.2 %) > 0.99
Previous PCI 6/45 (13.3 %) 9/45 (20.0 %) 0.396
Previous CABG 6/39 (13.3 %) 4/45 (8.9 %) 0.502
Time (hours, median, IQR) Admission – randomisation 2.8 (0.08–5.84) 1.87 (0.06–9.06) 0.994
Randomisation – angiography 3.04 (2.23–4.03) 70.05 (50.6–112.58) < 0.001
Angiography – PCI 0.37 (0.24–0.73) 96.52 (29-146.28) < 0.001
Angiography – CABG 114.75 (42.05–219.53) 275.25 (175.57–494.15) 0.012
Angiography-revascularisation 0.71 (0.29–63.69) 146.28 (82.04–296.96) < 0.001
Extent CAD One vessel 15/44 (34.1 %) 12/42 (28.6 %) 0.531
Two vessel 10/44 (22.7 %) 14/42 (33.3 %)
Three vessel 14/44 (31.8 %) 14/42 (33.3 %)
Infarct-related artery LAD 18/39 (46.2 %) 16/40 (40.0 %) 0.461
RCA 7/39 (17.9 %) 8/40 (20.0 %)
Circumflex 9/39 (23.1 %) 13/40 (32.5 %)
Left main 0/39 1/40 (2.5 %)
Graft 2/39 (5.1 %) 2/40 (5.0 %)
Treatment PCI 24/39 (61.5 %) 20/40 (50.0 %) 0.685
CABG 11/39 (28.2 %) 15/40 (37.5 %)
Medical 4/39 (10.3 %) 5/40 (12.5 %)
Primary endpoint (%) Combined endpointa 2/43 (4.7 %) 9/44 (20.5 %) 0.027
Death 0/43 (0.0 %) 1/44 (2.3 %) > 0.99
MI 1/43 (2.3 %) 1/44 (2.3 %) > 0.99
Recurrent ischaemia 1/43 (2.3 %) 8/44 (18.2 %) 0.030
Secondary endpoints (%) Enzymatic infarct sizeb 0.36 (0.13–0.73) 0.29 (0.05–1.10) 0.538
% patients without CKMB rise 22/44 (50.0 %) 18/32 (56.3 %) 0.590
Bleeding Any bleeding 9/43 (20.9 %) 10/44 (22.7 %) 0.839
Major bleeding 4/43 (9.3 %) 4/44 (9.1 %) > 0.99
CABG-related bleeding 6/43 (14.0 %) 8/44 (18.2 %) 0.592
CABG-related major bleeding 3/43 (7.0 %) 4/44 (9.1 %) > 0.99
CABG coronary artery bypass graft, CAD coronary artery disease, CKMB creatine kinase-MB, IQR inter quartile range, LAD left anterior 
descending, MI myocardial infarction, PCI percutaneous coronary intervention, RCA right coronary artery, TIA transient ischaemic attack.
aCombined primary endpoint = incidence of death, reinfarction and recurrent ischaemia at 30 day follow-up.
bSingle troponin T 72–96 h after admission (µg/l, median, IQR).
186 Neth Heart J (2016) 24:181–187
but at most reduces the incidence of recurrent ischaemia. 
This post-hoc analysis shows that the sub-group of patients 
initially hospitalised in non-PCI centres especially benefit 
from an early invasive strategy. A plausible explanation is 
the shorter waiting time between angiography and revascu-
larisation in these patients.
(RRR) for the combined endpoint of death, re-infarction 
or recurrent ischaemia at 30 days, driven by a reduction 
in recurrent ischaemia (RRR = 40 %, p = 0.058). These 
results are largely consistent with previously conducted 
randomised trials and meta analyses [9–11] and show that 
immediate intervention is not associated with a reduction 
in hard clinical endpoints (death or myocardial infarction) 
Fig. 3 Kaplan-Meyer curves for 
event-free survival from recurrent 
ischaemia for each of the 4 treat-
ment groups
 
Fig. 1 Forest plot of relative risk of primary and secondary endpoints 
at 30 days of follow-up in patients randomised to early or late interven-
tion in a PCI centre versus non-PCI centres. Data are numbers or per-
centages, unless otherwise indicated. Percentages are number of events 
divided by number of patients. Squares and horizontal bars represent 
within-subgroup relative-risk and 95 % CIs, respectively, on a log scale
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Fig. 2 Timing of procedures in 
PCI and non-PCI-centres for pa-
tients randomised to early or late 
intervention. Hosp hospitalisa-
tion, random randomisation, CAG 
coronary angiography, PCI percu-
taneous coronary intervention
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